Compugen (CGEN) Reports Q1 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Compugen Reports First Quarter 2017 Results
May 9, 2017 7:13 AM EDTHOLON, Israel, May 9, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today reported financial results for the first quarter ended March 31, 2017.
Anat Cohen-Dayag, Ph.D., CEO and President of Compugen, stated, "During this quarter we saw continuing scientific and therapeutic development advancements as well as business development progress in our four focus program areas:
COM701, an antibody drug candidate against PVRIG, a novel immune checkpoint target, with the potential to serve for both mono-... More